This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.85% and 1.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Collegium Pharmaceutical (COLL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -2.68% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 55.56% and 5.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Collegium Pharmaceutical (COLL) closed at $38.79 in the latest trading session, marking a -1.6% move from the prior day.
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
by Zacks Equity Research
AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron have been highlighted in this Screen of The Week article.
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
by Zacks Equity Research
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Time to Get These 5 Top Relative Price Strength Stocks
by Nilanjan Choudhury
APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.
3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
by Zacks Equity Research
Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.
Encompass Health (EHC), Piedmont to Build Loganville Facility
by Zacks Equity Research
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.
Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care
by Zacks Equity Research
Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice
by Zacks Equity Research
Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for February 29th
by Zacks Equity Research
UGP, HMC and COLL made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 29, 2023.